All Comments by Paul Coleman

  1. Treatment of Alzheimer's disease. New developments.
  2. Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome.
  3. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent.
  4. Neurofilament protein levels in CSF are increased in dementia.
  5. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain.
  6. APLP2, a member of the Alzheimer precursor protein family, is required for correct genomic segregation in dividing mouse cells.
  7. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome.
  8. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
  9. Chronic (-) deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain.
  10. Neuropathologic diagnosis of Alzheimer disease: consensus between practicing neuropathologists?
  11. Regulation of expression, phosphorylation and biological activity of tau during differentiation in SY5Y cells.
  12. Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain.
  13. Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease.
  14. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease.
  15. Aloys Alzheimer, a coworker of Emil Kraepelin.